Bearish engulfing pattern on Immunomedics could be a bad sign

Analyzing biotech companies is trickier than it is with other sectors. Many firms in the sector will lose money for years until a breakthrough happens and then, BAM they are profitable. Until that breakthrough happens, you are left to analyze the technical aspects of the stock and monitor the news from the company. One such company is Immunomedics (Nasdaq: IMMU), a clinical-stage biopharmaceutical company.

The company has lost money in each of the last three years and the losses have been increasing rather than decreasing. Even with such results, the stock hasn't been tanking. In fact the stock moved up quite nicely in 2017 and halfway through 2018. For 2019 the stock seems to a bit range bound between the $12 mark and the $20 mark. I know that is a rather large range, but the stock jumped from $4 to $16 in 2017.

What got my attention about Immunomedics currently was the pattern in the candlestick chart on November 6. The stock opened at $17.88 and closed at $17.18 which created a red bar on the chart. What makes it a bearish engulfing pattern is the fact that the open was higher than the previous day's high and the close was lower than the previous day's low—the body of November 6 engulfs the body for November 5.

In candlestick charting, this is known as a topping pattern. I circled two other bearish engulfing patterns from Immunomedics past and they both came at temporary high points for the stock. The one in September is particularly strong as the stock fell immediately from the $17.50 level to the $12.50 level in only two weeks.

In addition to the bearish engulfing pattern, the higher Bollinger Band was broken on November 4 and could indicate that the price could fall as the ticker heads toward the middle band. In 46 of 54 cases where Immunomedic's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued downtrend are 85%.

I mentioned how the company has been losing money, but let's look at some of the fundamental indicators from Tickeron. The fundamental analysis overview highlights figures that are in the upper third of ratings in green, and Immunomedics doesn't have any fundamental indicators with green highlights.

The best rating for the company is the Price Growth Rating at 38, indicating steady price growth. The Profit vs. Risk Rating for the company is 50, indicating well-balanced risk and returns. The average Profit vs. Risk Rating for the industry is 90, placing this stock better than average.

The Tickeron Valuation Rating of 65 indicates that the company is fairly valued in the industry. A rating of 1 points to the most undervalued stocks, while a rating of 100 points to the most overvalued stocks. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization.

The Tickeron SMR rating for this company is 98, indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents.

Immunomedics released earnings on October 30. The loss per share was $0.49 and that was worse than expected by analysts and it was worse than the $0.35 loss a year ago. Especially troubling was the fact that the company didn't generate any revenues in the third quarter of 2019. That is a scary statement right there.

Contributor

Harry Richardson|Expert

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume